Cochrane · systematic review · CD005225
Creatine for amyotrophic lateral sclerosis/motor neuron disease
Pastula, DM, Moore, DH, Bedlack, RS · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 3 · 100%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyCreatine for amyotrophic lateral sclerosis
Population: patients with amyotrophic lateral sclerosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tracheostomy‐free survival | no estimate extracted | 3 studies · 386 participants | High |
ALSFRS‐R slope Change in ALSFRS‐R / month | no estimate extracted | 3 studies · 386 participants | High |
FVC Slope Change in FVC / month | no estimate extracted | 2 studies · 211 participants | High |
Creatine for amyotrophic lateral sclerosis
Population: patients with amyotrophic lateral sclerosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tracheostomy‐free survival | no estimate extracted | 3 studies · 386 participants | High |
ALSFRS‐R slope Change in ALSFRS‐R / month | no estimate extracted | 3 studies · 386 participants | High |
FVC Slope Change in FVC / month | no estimate extracted | 2 studies · 211 participants | High |